VOLITIONRX LTD
About VOLITIONRX LTD
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.7M
- Net income
- -$23.4M
- Total assets
- $6.9M
- Market cap
- $15.4M
- Operating margin
- -1258.5%
- Net margin
- -1360.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.7M
- Operating expenses
- $23.5M
- Operating income
- -$21.7M
- Income tax
- $19
- Net income
- -$23.5M
Balance sheet
- Total assets
- $6.9M
- Current assets
- $2.1M
- Total liabilities
- $42.5M
- Current liabilities
- $12.2M
- Shareholders’ equity
- -$35.6M
Cash flow
- Operating cash flow
- -$19.7M
- Investing cash flow
- -$89.6K
- Financing cash flow
- $17.1M
- Net cash flow
- -$2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.4M
- Shares outstanding
- 11.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 25, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $23.4M in FY2025.
- Revenue grew 1819% from FY2021 to FY2025.
- Trading 92% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review VOLITIONRX LTD.
Write a review
News about VOLITIONRX LTD
News & sentiment via Polygon.io
